Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics

January 27, 2016

Company to focus on pipeline of Pentarins™ as a unique and promising approach to treating solid tumor cancers

Lead drug candidate PEN-221 targeting neuroendocrine and small cell lung cancers to advance into clinical studies in 2016

Codiak BioSciences Closes $61 Million Series B Financing

Codiak BioSciences Closes $61 Million Series B Financing

January 26, 2016

- Funds increase support for world-leader in exosome biology to $92 million

- Codiak aims to harness exosome potential in multiple therapeutic and diagnostic areas  

Strong 2015 Places Joule as a Global Leader in Scalable Ultra-Low Carbon Fuel Technologies

Strong 2015 Places Joule as a Global Leader in Scalable Ultra-Low Carbon Fuel Technologies

January 21, 2016

Bedford, Mass.—Jan. 21, 2016—Joule, the pioneer of drop-in liquid fuels from recycled CO2, announced today that it has gained significant traction in the acceleration and commercialization of environmentally sustainable ultra-low carbon fuel technologies in 2015. Joule also announced the formal completion of its acquisition of Red Rock Biofuels, a leading project development company of renewable jet and diesel fuel based on waste from biomass or other sources.

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

January 14, 2016

LYON, France--(BUSINESS WIRE)--Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.

Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing

Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing

January 12, 2016

CAMBRIDGE, Mass., January 12, 2016 – Syros Pharmaceuticals today announced the closing of a $40 million financing of preferred stock. New investor Deerfield Management Company led the financing, which also included participation from new investor Casdin Capital as well as existing investors Fidelity Management and Research Company, WuXi Healthcare Ventures, Polaris Partners, Redmile Group, Aisling Capital and Alexandria Venture Investments.

Black Duck Adds Container Scanning Capabilities to Hub Security Solution

Black Duck Adds Container Scanning Capabilities to Hub Security Solution

January 12, 2016

BURLINGTON, Mass.--(BUSINESS WIRE)--Black Duck, a global leader in automated solutions for securing and managing open source software, today announced the addition of comprehensive container scanning capabilities to its Hub software. DevOps teams will be able to map open source security vulnerabilities for applications, Linux distributions and other software in Docker and other Linux containers.

Moderna Announces Transition to a Clinical Stage Company, Provides Business Updates and Outlines 2016 Strategic Priorities

Moderna Announces Transition to a Clinical Stage Company, Provides Business Updates and Outlines 2016 Strategic Priorities

January 11, 2016

CAMBRIDGE, Mass., January 11, 2016 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced it is now a clinical stage company with its first Phase I study for mRNA 1440 currently underway in Europe. Moderna also announced it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for mRNA 1851, its second clinical program, with a Phase I study anticipated to begin in Q1 2016. mRNA 1440 and mRNA 1851 are infectious disease vaccines for undisclosed targets and indications.

Moderna Therapeutics Teams with Gates Foundation to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection

Moderna Therapeutics Teams with Gates Foundation to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection

January 12, 2016

CAMBRIDGE, Mass., January 12, 2016 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced a partnership with the Bill & Melinda Gates Foundation to advance the development of a novel, affordable combination of mRNA-based antibody therapeutics to help prevent human immunodeficiency virus (HIV) infection. The development efforts will be led by Valera, Moderna’s infectious disease-focused venture.

Evelo Therapeutics Establishes Core Executive Team

Evelo Therapeutics Establishes Core Executive Team

January 11, 2016

Cambridge, Mass., January 11, 2016/PRNewswire/ - Evelo Therapeutics, a biotechnology company pioneering the development of microbiome-based therapies for cancer, today announced that it has established its core executive team with the appointment of Mark Bodmer, Ph.D., as chief scientific officer and president of research and development; Kareem Reda as vice president and director of business development and strategy; and William DeVaul as vice president of intellectual property.

Agios Outlines Key 2016 Goals and Priorities

Agios Outlines Key 2016 Goals and Priorities

January 11, 2016

SAN FRANCISCO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today outlined the company’s 2016 strategy and expected clinical development and research milestones in conjunction with the 34th Annual J.P. Morgan Healthcare Conference in San Francisco.